Redirecting to https://www.wallstreet-online.de/nachricht/20269396-beyondspring-announces-new-analyses-of-dublin-3-phase-3-study-showing-survival-benefit-of-plinabulin-docetaxel-post-anti-pd-l-1-for-non-squamous-egfr-wt-nsclc-and-a-reduction-brain-metastasis-compared-to-docetaxel-at-naclc-2025